Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Mydecine Innovations Group Inc
(OP:
MYCOF
)
0.0106
+0.0004 (+3.92%)
Streaming Delayed Price
Updated: 11:35 AM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mydecine Innovations Group Inc
< Previous
1
2
3
4
5
6
7
Next >
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Private Placement; Interim Changes to Management and Board
August 19, 2022
Via
Investor Brand Network
Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
August 16, 2022
After the resignation of several key board members on August 12, Mydecine Innovations Group (OTC: MYCOF) reported its financial results. For the period corresponding to the six months ended June 30,...
Via
Benzinga
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
July 19, 2022
Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications.
Via
Benzinga
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Designs Family of MDMA Analogs, Files Full Patent Application
July 19, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved
June 17, 2022
Biotech company Mydecine Innovations Group (OTC: MYCOF) received FDA approval for their novel proprietary MYCO-001. This is the first clearance of the company’s drug product.
Via
Benzinga
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces First Clearance of MYCO-001 for Government-Funded Study
June 17, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Releases Status Update, Announces New Member of the Board
June 09, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Mydecine Reports Financial Results For 2021
April 01, 2022
Via
Benzinga
American Billionaire Entrepreneurs Bet Millions on Psychedelics
May 10, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman...
Via
FinancialNewsMedia
Exposures
Product Safety
Mydecine Announces 1-for-50 Reverse Stock Split
April 14, 2022
The board of directors of Mydecine Innovations Group Inc. (OTCPK:MYCOF) voted in favor of completing a reverse stock split. With this action, the company will consolidate all issued and outstanding...
Via
Benzinga
Why Psychedelics Could Soon Replace Antidepressants
April 13, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults...
Via
FinancialNewsMedia
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements
April 12, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Working to Capitalize on Psychedelics Therapeutics Market’s Growth
April 08, 2022
Via
Investor Brand Network
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
April 06, 2022
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector.
Via
Benzinga
Demand for Toad Venom Rises Along With the Booming Psychedelics Market
March 30, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 30, 2022 – Depression and anxiety affect millions around the world and the venom of a toad is the latest psychedelic...
Via
FinancialNewsMedia
BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Moving to Become Trusted Source of Effective Medication-Based Treatments
March 29, 2022
Via
Investor Brand Network
Exposures
Product Safety
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces IRB Approval for Planned Smoking Cessation Study
March 24, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers a Glimpse into its R&D Pipeline, Patent Strategies, and Clinical Trials at March Investor Conferences
March 18, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Playing Pivotal Role in Renaissance of Psychedelics
March 17, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Strengthening Leadership Role in Psychedelics Space
March 10, 2022
Via
Investor Brand Network
Topics
Supply Chain
Exposures
Supply Chain
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Participation Schedule for March Investor Conferences
March 03, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Pre-IND Meeting with FDA for Smoking Cessation Study
March 01, 2022
Via
Investor Brand Network
Exposures
Product Safety
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005
February 28, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Addresses Its ‘A to Z’ Approach to Drug Development in New Video
February 24, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics
February 23, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs
February 16, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Distinctive with Phased Approach to Novel Therapeutics Development
February 15, 2022
Via
Investor Brand Network
Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience
February 15, 2022
Via
Investor Brand Network
Topics
Supply Chain
Exposures
Supply Chain
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
February 09, 2022
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,...
Via
Benzinga
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans
February 08, 2022
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.